Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Overview
Nutriband Inc is a Florida-based pharmaceutical company specializing in the development of transdermal drug delivery systems that incorporate advanced abuse-deterrent technologies. Its core business revolves around transdermal pharmaceutical products engineered to mitigate the risks of drug abuse, misuse, diversion, and accidental exposure, with a special emphasis on addressing the global opioid crisis. Utilizing proprietary technology that integrates aversive agents into transdermal patches, Nutriband is dedicated to improving patient safety while ensuring essential medications remain accessible for those in need.
Advanced Abuse-Deterrent Technology
The company’s flagship innovation, AVERSA technology, is designed to deter the oral abuse of potent drugs by utilizing taste aversion methods. This technology can be incorporated into various transdermal patches, a critical step toward preventing accidental exposures—particularly in vulnerable populations such as young children. The patented approach provides an additional safeguard by making the potential for abuse less appealing, thereby enhancing the overall safety profile of drugs with abuse potential.
Business Model and Operations
Nutriband Inc generates revenue primarily through the sale of consumer transdermal and coated products, as well as through contract manufacturing services provided by its wholly owned subsidiary, Pocono Pharma. The company leverages its strategic partnerships with top industry players to extend its market reach, including engagements with major retailers and established pharmaceutical manufacturing organizations. This diversified revenue approach not only supports the current portfolio but also positions Nutriband as a flexible partner in both the healthcare and contract manufacturing sectors.
Strategic Partnerships and Intellectual Property
A cornerstone of Nutriband’s success is its robust global intellectual property portfolio, which spans across more than 40 countries including the United States, Europe, Japan, and Australia. Such extensive protection underpins its innovative AVERSA technology and provides a competitive edge in the increasingly critical field of abuse-deterrent transdermal systems. Strategic alliances with industry experts such as Kindeva Drug Delivery further reinforce its position by ensuring that large-scale manufacturing processes align with FDA guidelines and international industry standards.
Market Position and Industry Significance
Operating at the nexus of pharmaceutical innovation and patient safety, Nutriband Inc is positioned distinctively in the competitive landscape of transdermal drug delivery systems. Its strategic focus on developing abuse-deterrent products addresses a significant unmet need in the market, particularly in the context of managing opioid-related risks without compromising therapeutic access. Through its commitment to evolving industry standards and enhancing product safety, Nutriband has established itself as a forward-thinking entity within a critical market segment.
Product Portfolio and Future Applications
While its lead product, an abuse-deterrent fentanyl patch, remains at the forefront of its development efforts, Nutriband is actively expanding its portfolio to include additional transdermal therapies. By integrating its core AVERSA technology across multiple product lines, the company aims to address a wide spectrum of medications with abuse potential, including opioids and stimulants. This strategy not only diversifies its technology applications but also solidifies its reputation as an innovator in transdermal pharmaceutical solutions.
Commitment to Safety and Regulatory Compliance
At the heart of Nutriband’s mission is a dedication to enhancing patient safety through rigorous research, development, and close adherence to regulatory standards. The company emphasizes clear, methodical approaches that streamline market entry while upholding the highest safety measures. This balance of innovation and compliance is critical in a market where the prevention of misuse and accidental exposure is of paramount concern.
Overall, Nutriband Inc exemplifies a strategic blend of innovative product development, methodical market expansion, and a steadfast commitment to patient safety. Its robust technology platform, significant IP portfolio, and established industry partnerships underscore its role as a key contributor to the evolution of abuse-deterrent pharmaceutical products.
Nutriband Inc. (NASDAQ: NTRB) announced its financial results for the fiscal year ending January 31, 2022, reporting record revenue of $1.4 million, up 56% from the previous year. Key achievements include a successful uplisting to Nasdaq in October 2021, raising gross proceeds of approximately $8.7 million, and a partnership with Kindeva Drug Delivery for the AVERSA™ Fentanyl patch. Despite a net loss of $6.4 million, stockholders' equity increased 28% to $11.9 million. The company aims to capitalize on the growing market for abuse deterrent fentanyl patches.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that the USPTO published a patent for its AVERSA™ technology aimed at preventing opioid misuse through a transdermal system. The patent, US Patent 11,246,840, was issued on February 15, 2022, and supports the development of the AVERSA Fentanyl patch. Nutriband has entered a feasibility agreement with Kindeva Drug Delivery to incorporate this technology in its lead product candidate.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) will participate in Benzinga ALL ACCESS on February 4, 2022, featuring CEO Gareth Sheridan at 10AM ET. The event can be streamed live here. Nutriband specializes in developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing their AVERSA™ technology. This technology aims to prevent the misuse and accidental exposure of drugs. For more details, visit www.nutriband.com.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced the receipt of a notification from the USPTO confirming the issuance of a patent for its AVERSA™ transdermal abuse deterrent technology.
This technology aims to prevent the misuse of drugs by incorporating aversive agents into transdermal patches. The patent secures the company’s lead product, AVERSA™ Fentanyl, which could become the first fentanyl patch with abuse deterrent properties. Nutriband is also expanding its pipeline to include other drugs, enhancing safety against misuse.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has expanded its product development pipeline for its AVERSA™ abuse deterrent transdermal technology. The lead product, AVERSA Fentanyl, could tap into a market worth $80 - $200 million. Additionally, AVERSA buprenorphine and AVERSA methylphenidate are now part of the pipeline, targeting existing products with abuse potential. The technology aims to deter misuse while ensuring drug availability. A feasibility agreement with Kindeva Drug Delivery has initiated the development of AVERSA Fentanyl, enhancing Nutriband's strategic focus on abuse deterrent formulations.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced a feasibility agreement with Kindeva Drug Delivery to develop its lead product, AVERSA™ Fentanyl, utilizing AVERSA™ abuse deterrent technology. This partnership aims to adapt Kindeva's transdermal manufacturing process for AVERSA technology. The technology includes aversive agents to prevent drug abuse and is supported by a robust patent portfolio. CEO Gareth Sheridan expressed optimism about improving safety for fentanyl users while maintaining accessibility for patients in need.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has completed a market assessment for its lead product, Aversa™ Fentanyl, an innovative abuse-deterrent fentanyl transdermal system. Conducted by Health Advances, the analysis suggests that Aversa has the potential for peak annual US sales ranging from $80-200 million within five years post-launch. The company aims to follow a 505(b)(2) NDA regulatory path towards FDA approval, targeting a safer alternative amidst rising concerns over opioid abuse. This product may redefine the transdermal fentanyl market by introducing crucial safety features.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that the Korean Intellectual Property Office has issued a full patent for its Abuse and Misuse Deterrent Transdermal System, related to its lead technology AVERSA. This technology aims to prevent opioid abuse through taste aversion methods. A prior notice of allowance was issued in December 2020. Nutriband focuses on developing transdermal pharmaceutical products, with AVERSA designed to mitigate risks associated with abuse, misuse, and accidental exposure.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of December 29, 2021, the company had 7,773,962 shares outstanding. This buyback aims to enhance shareholder value and signal confidence in the company's future. Nutriband is focused on developing transdermal pharmaceutical products, particularly an abuse-deterrent fentanyl patch using its AVERSA™ technology.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced plans to offer contract manufacturing services for liquid-based topical products, following its recent cGMP certification. This certification relates to Pharmaceutical OTC GMP, 21 CFR Part 211/210, enhancing the company's manufacturing capabilities. CEO Gareth Sheridan stated that expanding these capabilities aligns with the company's revenue growth strategy for 2022. Nutriband is primarily focused on developing transdermal pharmaceutical products, including its abuse deterrent fentanyl patch utilizing AVERSA technology.